High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Experimental evidences supported the benefit of Simvastatin in subarachnoid haemorrhage.
Moreover, Simvastatin is a potent agent in achieving low-density lipoprotein (LDL) reduction
with a proven safety profile. However, there is no clinical data to compare the efficacy of
different dosage regimens (namely whether high-dose regimen is better) and related
cost-effectiveness analysis, although biochemical actions and related neuroprotective
mechanisms were thought to be dosage-related. This gap in knowledge is important, on how to
implement the use of statin and interpret different trial results. With these in mind, the
investigators designed the current study.
Hypothesis:
Daily Simvastatin 80mg (high dose) treatment given within 96 hours of the ictus over three
weeks will reduce incidence and duration of delayed ischemic deficits following subarachnoid
haemorrhage when compared to daily Simvastatin 40mg (normal dose) treatment, leading to
improvement in clinical outcome, which translates into advantage in terms of
cost-effectiveness.